We also use them to share usage. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. THERATECHNOLOGIES INC. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Provides Details About R&D Day Webcast. Stockhouse. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. T. The business had revenue of $27. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Stockhouse. Who is Theratechnologies. By continuing to use our service, you agree to our use of cookies. H. Katana shareholders will. TH | May 19, 2023. (TH. A high-level overview of Theratechnologies Inc. It's a different kind of fat that may require a different type of treatment. com uses cookies on this site. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. 1M. 17% from a day low at $1. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. By continuing to use our service, you agree to our use of cookies. 9 million, adjusted EBITDA of $2. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Stockhouse. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. com uses cookies on this site. Investor inquiries: Elif McDonald. 63. 20% from a day low at $1. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. MONTREAL, Feb. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Theratechnologies Inc. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. 51 to 200 Employees. RESSOURCES. 54% and a negative trailing twelve-month return on equity of 1,116. stock price gained 6. L. This news release constitutes a. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 0. com uses cookies on this site. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. By continuing to use our service, you agree to our use of cookies. Stockhouse. com uses cookies on this site. October 13, 2022 07:30 ET | Source: Theratechnologies. We also use them to. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. Company Description: Theratechnologies is pepped up on peptides. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Stockhouse. VANCOUVER, British Columbia, Nov. The company develops treatments for lipodystrophy . The abstract and poster can be found on Theratechnologies’ website. 60%. European Headquarters. By continuing to use our service, you agree to our use of cookies. Gary Littlejohn Stockhouse. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. We also use them to share usage information with our partners. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902 combines Theratechnologies’ proprietary peptide to. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. 9 million and US. The Theratechnologies Inc. MONTREAL, Jan. 28 $1. ASP | Complete Acerus Pharmaceuticals Corp. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. THERATECHNOLOGIES INC. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. Website. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. 3. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Nov. Stockhouse. 22M. Stockhouse. MONTREAL, Nov. 4% from the stock's current price. 00 to $36. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. 67% from the latest price. 49%) At close: 04:00PM EST 1. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Heures de négociation. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. com. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Consensus forecasts updated Jul 21. Stockhouse. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). 69, 1. FY2022 revenue. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Cookies are used to offer you a better browsing experience and to analyze our traffic. The firm offers its product under the brand name of. Follow. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The financial results presented in this press release are taken from the. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. Pour les émetteurs. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. MONTREAL, Oct. Theratechnologies Inc. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. L. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Theratechnologies (THTX) Stock Price, News & Analysis $1. This news release constitutes a “designated news release” for the purposes of the. stock price gained 1. 66% compared to the previous year's 69. 54% and a negative trailing twelve-month return on equity of. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. TORONTO, May 19, 2023. We currently market prescription products for people with HIV in the United States. Revenues have been growing at an average rate of 10. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. Investor Relations. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. 00%. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. Stockhouse. 's motion for leave to commence. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. 5000 0. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. When this page refreshes you will be logged in with the new address. ("Theratechnologies" or the "Company"). Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. S. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. US Headquarters. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. T. 46. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. By continuing to use our service, you agree to our use of cookies. Theratechnologies has generated ($1. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. com. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. 1. : Renegotiated Lease to Generate Substantial Annual Savings. See a list of the most recent Stock Forum posts on Stockhouse. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. R. Visit the TSX ETF Investor Centre to access our screener and comparison tool. 49) by $0. First Quarter Fiscal 2022 Financial Results. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies develops and commercializes innovative therapies. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. com uses cookies on this site. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. We changed the address of the Stockhouse website from to stockhouse. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Stockhouse. 82 million. 1-438. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. A live webcast of Dr. Theratechnologies Inc. Volume has increased on the last day along with the price, which is a. com. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. Patient assistance: 833-238-4372. - 2023 Q3 positive adjusted EBITDA to be. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. By continuing to use our service, you agree to our use of cookies. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies Inc. Theratechnologies Inc. NEW YORK, Dec. 00. 86 million for the quarter. -986. Investor inquiries: Elif McDonald. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. 26 +15. Theratechnologies reduces R&D head count to compensate for sales setback. stock news by MarketWatch. By continuing to use our service, you agree to our use of cookies. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. This news release constitutes a “designated news release” for the purposes. Senior Director, Investor Relations. Montréal, Québec, Canada . 00. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. Losses were -47. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. com. Cookies are used to offer you a better browsing experience and to analyze our. Theratechnologies Stock Price, News and Company Updates. (TH. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. By continuing to use our service, you agree to our use of cookies. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2 million. According to 3 analysts, the average rating for THTX stock is "Buy. Theratechnologies inc. 9 million as at August 31, 2023. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. 4% annually. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. By continuing to use our service, you agree to our use of cookies. TH | September 5, 2023. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Investor Relations. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. Stockhouse. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. Cookies are used to offer you a better browsing experience and to analyze our traffic. Betteryear2. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. MONTREAL, Feb. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. Montréal, Québec, Canada . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 89 52. Story. There are 102 news items for this page. MONTREAL, Jan. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. 67, which is an increase of 1,144. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Stockhouse. ir@theratech. Stockhouse. Saint-Laurent, Canada. Senior Director, Investor Relations. 2% per year. Stockhouse. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. communications@theratech. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Browse posts by Sector and Subsector. com uses cookies on this site. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. S. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . (TH. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies Inc. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. is a pharmaceutical company. NCU. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Stockhouse. Competitors: Unknown. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Senior Director, Communications & Corporate Affairs. com uses cookies on this site. “This is yet another major achievement for our oncology program. Last Reviewed: February 24, 2023. 08). Theratechnologies inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. B2Gold Declares Fourth Quarter 2023 Dividend. . (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. e. Theratechnologies Inc. This suggests a possible upside of 2,471. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. ( THTX 3. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies had a negative net margin of 36. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. . . By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Biopharmaceutical company Theratechnologies Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. In the United States, Trogarzo ® (ibalizumab. 11/05/2020 4:15:02 PM. Stockhouse. On average, they expect the company's stock price to reach $36. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. We also use them to share usage information with our partners. 2. The company had revenue of $20. Trogarzo® and. If you have HIV, it's important to know the difference. Once expert advice is considered, the Company. Montreal-based biopharmaceutical company Theratechnologies Inc. MONTREAL, Jan. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2013-04-03 | TSX:TH) Theratechnologies Inc. MONTREAL, Feb. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. " The 12-month stock price forecast is $18. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. ET. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage. US Headquarters. MONTREAL, Sept. It is the Company’s proprietary. OTCQX – this is the premium tier of OTC stocks. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. By continuing to use our service, you agree to our use of cookies. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. 5%. 71. 124. We also use them to share usage information with our partners. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. znewcar1. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . C. 69 to $1. Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. 35 as of 10:41 a. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. 514-336-7800. com uses cookies on this site. com uses cookies on this site. 4. Gary Littlejohn. Cookies are used to offer you a better browsing experience and to. We also use them to share usage. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12.